Extended treatment with antithymocyte globulin (ATGAM) in renal allograft recipients
- PMID: 392832
- DOI: 10.1097/00007890-197911000-00003
Extended treatment with antithymocyte globulin (ATGAM) in renal allograft recipients
Abstract
Twenty renal allograft recipients were treated with antithymocyte globulin (ATGAM; ATG) for up to 16 weeks in addition to azathioprine and prednisone, while 20 controls received no ATG. The ATG group showed a lower incidence of first rejection episodes during the first month after transplantation, and also a better functional graft survival rate up to 2 years after transplantation. The results in this early ATG trial were better than those in subsequent trials which used 14-day treatment regimens. Longer treatment deserves another look.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources